Baird analyst Brian Skorney raised the firm’s price target on Vertex Pharmaceuticals to $325 from $280 and keeps a Neutral rating on the shares. The analyst said they put up another impressive quarter and the pipeline has really come into focus with next-gen triple data coming by year-end, which can extend the franchise’s IP further while improving margins.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $384 from $342 at Barclays
- Vertex Pharmaceuticals reports Q1 EPS $2.69, consensus $3.00
- Vertex options imply 3.8% move in share price post-earnings
- VRTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Vertex announces U.S. FDA approval for expanded use of Trikafta
